Sun Pharma Share Price Target 2022 , 2023 , 2024 , 2025 & 2030

Sun Pharma Share Price Target The time period indicated by the analyst is one year, during which the price of Sun Pharmaceutical Industries Ltd. can achieve a specific goal. Sun Pharmaceutical Industries Ltd., incorporated in 1993, is a large cap (market cap 195,641.77 crore) operating in the pharmaceutical sector. Sun Pharmaceuticals Industries Ltd last traded at 838.80, up 2.91% on the NSE. Sun Pharmaceutical Industries’ share price is on an upward trend, so we believe similar market segments have been very popular over a period of time. ICICI Securities has repurchased the purchase of Sun Pharmaceutical Industries shares at a target price of Rs 959.

Sun Pharma Share Price Target 2022 , 2023 , 2024 , 2025 & 2030

Sun Pharma Share Price Target

The stock is trading above weekly resistance and a drop can only be expected on trading below 820.13. Sun Pharmaceuticals Industries Limited SUNPHARMA’s outlook for tomorrow’s movement on December 29, 2021 looks optimistic. Sun Pharmaceutical Industries shares hit a more than five-year high of Rs 846.80, up 2% on the BSE on Wednesday; intraday trading, revenue growth is expected to be significant on the back of good specialization and strong domestic performance. Sun Pharma Stock Price Forecast for the Day and Tomorrow – Using the MACD Indicator Check out the Sun Pharma Stock Price Forecast using the MACD indicator to see if you need to buy, sell or hold those stocks in order to trade.

Similarly, you can buy Sun Pharma at the current market price with a target of Rs 880 to Rs 920 while holding a stop loss at Rs 804. Check daily Sun Pharma stock price target for intraday and Sun Pharma stock price prediction for tomorrow, for short-term trading and long-term investing. Sun Pharma Stock Price Prediction or Target – Using the Camarilla Equation View the intraday, tomorrow and short term forecast of Sun Pharma stock price using the Camarilla Equation.

CLSA maintained its buy rating for Sun Pharma following September quarter results, but raised its 12-month target price to Rs 1,050 from Rs 960 earlier. Citigroup maintained its buy rating for Sun Pharma after second quarter results and raised its target price to Rs 1,000.

Sun Pharma Share Price Target 2022 , 2023 , 2024 , 2025 & 2030

The complaint alleges that the parent company Sun is responsible for Ranbaxy, and Ranbaxy has unfairly obtained the ability to suspend business of all imitation versions of Valcyte, Diovan, and Nexium for many years through a series of misstatements and omissions. They recommend buying shares in Dr Reddys, Sun Pharma, Cipla and Divis Lab today. Investors can initiate an impulse purchase of Dr. Reddys at the current market price with a maximum target of 5,340 rupees and a stop loss of 4,970 rupees. Cequa’s sales risk still exists, and similar Restasis products may be produced,” the brokerage firm said in its updated inventory.

According to Graham’s internal equation, you should invest in stocks if the current stock price is undervalued. This indicator helps the trader to predict the stock price and trade accordingly. Breaking news is collected from a variety of sources and can have a positive or negative impact on stock prices in the short term.

Main Product Segments / Revenues Sun Pharmaceutical Industries Ltd. includes pharmaceutical and other operating revenues for the year ended 31 March-2021. Some pharmaceutical stocks have been sold and, according to experts, they can be bought for further growth in the next 2-3 months. We rate the V-Guard at 35x P / E per share on June 23 to achieve a target price of INR 265.

Sun’s strong (net cash) balance sheet is likely to foster special spending and non-organic initiatives. We have increased our TP SOTP to INR 1,800 to accommodate price increases and potential benefits from new business development. Sun Pharmaceuticals Industries Limited SUNPHARMA’s tomorrow forecast for December 29, 2021 shows signs of strength. SunPharmaceuticals’ target projections for February 2022 are 841.55, 808.48, 775.4 up and 665.65, 698.73, 731.8 down.

SunPharmaceuticals’ target forecasts for Friday, February 11, 2022 are 916.53, 857.44, 798.34 and 654.27, 713.37, and 772.46, respectively. The flagship company Reliance Industries Limited is a Fortune Global 500 company and the largest private company in India. The company reported net income after tax for the most recent quarter of Rs 2,088.73. As of September 30, 2021 to 2021, the founder owns 54.48% of the company’s capital, while FII owns 12.07% and DII owns 21.72%.

However, given the discerning appraisal, we repeat DECREASE as all positives are judged fairly. The single-digit portfolio price increases from low to medium were necessary to combat inflation and maintain margins. The company reported a net income after tax of Rs 2,088.73 in the most recent quarter.

Since big caps are important to you, here is our bluechip stock buying guide. Currently, there seems to be a trend where stocks in sectors were popular during this period.

LKP Wealth Advisory Ltd. Registered as an investment consulting company by the Securities Board of India, SEBI registration number. Our clients, third parties or anyone else are not authorized to forward or transmit, at our choice, any other information we provide to anyone, received directly or indirectly from them.

Marketing Efforts Support Illumya’s Strong Performance: FY21 reported 51% y / y sales of specialty products Ajanta Pharma reported strong numbers for fiscal 2Q22 that beat forecasts for sales.

Strong selling of livelihoods has resulted in a ratio of unsold reserves to low-level reserves with LPG, which currently has a year’s supply to sell its livelihoods. The pharmaceutical company reported a pre-tax profit of Rs 1,804.2 in the first quarter of fiscal year 22, compared with a pre-tax loss of Rs 283.9 crore in the first quarter of fiscal year 21.

Sun Pharma’s research and development division includes about 2,000 scientists, and investments account for approximately 8% of annual revenue. In the second quarter of fiscal 22, Sun Pharma reported excellent results for the second quarter of fiscal 22, with sales up 12.5% ​​YoY to Rs.

Performance data provided represents past results and does not guarantee future results. Nothing contained in this document constitutes an offer to sell or a call to buy any securities.

Its main target markets include India, Russia, Romania, Nigeria, South Africa and Myanmar. On the EBITDA margin, management expects to maintain the current rate in fiscal 22. Its production units are located, among others, in India, the USA and Brazil.

Leave a Comment